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Purpose: To describe the clinical and molecular characteristics of two families with autosomal dominant Best disease
and atypical electrooculography (EOG).
Methods: Four affected individuals from two families were ascertained. Detailed ophthalmic examinations, refraction,
and biometry (anterior chamber depth [ACD] and axial length [AL]), gonioscopy, optical coherence tomography of the
anterior segment and retina, retinal imaging, and electrophysiological assessment were performed. Arden ratios from EOG
testing were calculated by direct measurement of the light peak to dark trough amplitudes. Mutations in bestrophin 1
(BEST1) were identified by bidirectional Sanger sequencing. In family 1, segregation of BEST1 alleles was performed by
assaying four microsatellite markers (D11S935, D11S4102, D11S987, and D11S4162) that flank BEST1.
Results: The proband from family 1 (three of four siblings affected with Best disease) was 42 years old with bilateral
macular vitelliform lesions, advanced angle closure glaucoma (ACG), a normal electroretinogram, and no EOG light rise.
Her 44-year-old brother had similar fundus appearances and an EOG light rise of 170%. Their 48-year-old sister had a
normal left fundus, whereas the right fundus showed a vitelliform lesion and subretinal thickening. There was no EOG
light rise detectable from either eye. Mutation analysis of BEST1 showed all affected siblings to be heterozygous for a
missense mutation, c.914T>C, p.Phe305Ser. Their unaffected sister had an EOG light rise of 200%, a normal fundus
appearance, and did not harbor the BEST1 mutation. Haplotype analysis of family 1 showed that the affected brother with
the 170% EOG light rise had inherited the same nondiseased parental BEST1 allele as his unaffected sister. The other two
affected sisters with undetectable EOG light rises shared a different nondiseased parental BEST1 allele. An unrelated 53-
year-old female carrying the same c.914T>C, p.Phe305Ser mutation showed typical features of Best disease and an EOG
light rise of 180%. All four siblings from family 1 had shorter axial biometry (ACD range 2.06–2.74 mm; AL range 20.46–
22.60 mm) than the normal population, contributing to their risk of ACG development. Proband 2 had deeper ACDs (2.83
mm OD and 2.85 mm OS), but similar ALs (21.52 mm OD and 21.42 mm OS) compared to family 1. She had no
gonioscopic evidence of angle closure.
Conclusions: A near normal EOG light rise is uncommon in molecularly confirmed Best disease, and in the present report
is associated with the same mutation in two families, suggesting a specific role for this amino acid in the retinal pigment
epithelium dysfunction associated with this disorder. Haplotype analysis in family 1 was consistent with an effect of the
nondisease allele in mediating the presence of an EOG light rise. Clinical assessment of ACG risk is recommended for
BEST1 mutation carriers and their first degree relatives.
Best disease (OMIM 153700) is an autosomal dominant
macular  dystrophy  characterized  by  vitelliform  macular
lesions,  a  normal  electroretinogram  and  reduction  of  the
electooculogram  (EOG)  light  rise.  Best  disease  was  first
linked  to  bestrophin-1  (BEST1;  VMD2)  in  1998  [1,2].
Mutations in BEST1 have since been found to be causative of
other  distinctive  retinal  dystrophies,  including  autosomal
dominant  vitreoretinochoroidopathy  (ADVIRC;  OMIM
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193220) [3–7], autosomal recessive bestrophinopathy (ARB;
OMIM 611809) [8–10], adult vitelliform macular dystrophy
[11,12], and more recently, what was described as “concentric
retinitis pigmentosa” [13]. A severely reduced EOG light rise
remains the most sensitive clinical test for the diagnosis of all
bestrophinopathies [14].
The BEST1 gene encodes bestrophin-1, a transmembrane
protein located in the basolateral membrane of the retinal
pigment  epithelium  (RPE)  [15–18].  Current  available
evidence suggests that the EOG light rise results from chloride
conductance across the basolateral membrane of the RPE
[19].  Exogenous  expression  of  bestrophin-1  produces  a
chloride ion conductance, and bestrophin-1 may function as a
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2272calcium-sensitive chloride channel directly responsible for
generating the light rise of the EOG [20]. It has been recently
suggested that bestrophin-1 may indirectly modulate the light
rise component of the EOG in vivo [20–24].
The clinical, electrophysiological, and molecular genetic
findings in two families with Best disease are presented in this
report. Both families carry the same mutation in the BEST1
gene,  and  each  family  had  one  individual  unexpectedly
showing a good EOG light rise.
METHODS
Five subjects (aged 42 to 53) from two families were recruited
from  clinics  at  Moorfields  Eye  Hospital.  Slit-lamp
examinations,  including  dark-room  gonioscopy  performed
with a 1 mm slit-beam with a one-mirror Goldmann-style lens
(Magnaview  goniolens,  Ocular  Instruments,  WA),
applanation  tonometry,  and  disc  and  fundus  examinations
with  an  aspheric  lens  were  conducted.  Autorefraction
(Humphrey  autorefractor;  Carl  Zeiss  Meditec,  Jena,
Germany)  and  axial  biometry  measurements  of  anterior
chamber depth (ACD) and axial length (AL) were performed
(IOLMaster,  Carl  Zeiss  Meditec,  Dublin,  CA).  Fundus
imaging  included:  autofluorescence  (HRA  2;  Heidelberg
Engineering,  Heidelberg,  Germany),  optical  coherence
tomography (3D-OCT; Topcon, Paramus, New Jersey), and
fundus color photography (Topcon). Anterior segment OCT
(AS-OCT) was performed under dark-room conditions when
angle closure or secondary glaucoma was suspected (Visante;
Carl Zeiss Meditec, Dublin, CA).
Standard  electrophysiology  was  performed  that
incorporated the relevant ISCEV standards [25–27]. In short,
EOG testing was performed with surface electrodes placed at
the medial and lateral canthi of each eye. Thirty degree eye
movements were recorded for 10 s each minute during 15 min
dark adaptation, followed by a further 10–15 min in full-field
(Ganzfeld) light adaptation (100 cd/m2). The amplitude of the
dark trough and light peak were directly measured and Arden
ratios calculated [25]. The EOG recordings from these two
families were independently measured by three observers (SL,
GEH, and CH) and average values used. Normative data were
provided by 30 individuals aged between 30 and 60 years of
age with no ocular abnormalities. One eye from each subject
was randomly selected and used to establish the normative
data.
Genomic DNA was extracted from peripheral blood with
the Qiagen Blood DNA extraction kit (Qiagen, Crawley, UK).
Bidirectional Sanger sequencing analysis of the entire coding
regions of BEST1, including the splice donor and acceptor
sites of the gene, was performed with BigDye 3.1 (Applied
Biosystems,  Warrington,  UK).  Primer  sequences  and
annealing temperatures are shown in Table 1. The cDNA is
numbered  according  to  Ensembl  transcript  ID
ENST00000378043, in which +1 is the A of the translation
start codon.
Haplotype  analysis  was  performed  in  one  family  by
genotyping four microsatellite markers that flank the BEST1
gene:  D11S935,  D11S4102,  D11S987,  and  D11S4162,
available on the ABI linkage mapping set v.2.5-MD10. PCR
was performed on a thermal cycler in a total volume of 9 μl
containing 100 ng of genomic DNA, 0.2 μl of fluorescently
labeled microsatellite markers (ABI, Foster City, CA), and
equal volumes of ABsoluteTM QPCR-mix (ABgene; Thermo
Scientific, Epsom, UK). Reactions were performed with the
standard thermocycling profile for all markers. This consisted
of an initial denaturation (95 °C) for 15 min followed by 35
cycles of 94 °C for 60 s, 57 °C for 60 s, and 72 °C for 60 s,
with a final extension step of 72 °C for 12 min. One microliter
of  each  PCR  product  was  diluted  in  12  μl  of  the  HiDi
formamide  containing  2.5  μl  of  GeneScanTM-500  LIZ  ®
TABLE 1. PRIMER AND ANNEALING CONDITIONS FOR BESTROPHIN-1 (BEST1) SEQUENCING.
Annealing temperature
(°C)
Additional information Primer name Sequence 5′-3′
    Exon 2F CACCTGCTGCAGCCCACTGCC
61   Exon 2R CTTGTAGTGAACTGGTACACTGGCC
    Exon 3F GGACAGTCTCAGCCATCTCCTCG
59   Exon 3R GCAGCTCCTCGTGATCCTCCCCTGG
    Exon 4F CTAGGCCCGCTCGCAGCAGAAAGC
60 10% DMSO Exon 4R CTTCCATTCCTGCCGCGCCCATCTC
    Exon 5/6F CATCCCTTCTGCAGGTTCTC
59   Exon 5/6R CTTGGTCCTTCTAGCCTCAGTTTC
    Exon 7F CTGGAGCATCCTGATTTCAGGGTTC
59   Exon 7R CTCTGGCCATGCCTCCAGC
    Exon 8/9F GCTGGCTTTGAGGAGTTCTGCCTG
59   Exon 8/9R GTGCTATTCTAAGTTCCTAGGCAG
    Exon 10F GTAAGGGAGAAGTAAGGCCAGGTG
59   Exon 10 R GTAGGTCCAGTGTGCTCTGGCAG
    Exon 11F GAAGGGACCTTCCATACTTATG
59   Exon 11R CATTAAAGGCTGAAGTAGTCTGGG
Molecular Vision 2011; 17:2272-2282 <http://www.molvis.org/molvis/v17/a247> © 2011 Molecular Vision
2273fluorescent  dye  (Applied  Biosystems).  The  samples  were
denatured for 5 min at 95 °C, snap-frozen on ice for 5 min,
and centrifuged before loading onto the ABI Prism ® 3730
DNA  Analyzer.  The  GeneMapper  version  4.0  program
(Applied Biosystems) was used to score the genotypes.
All  participating  individuals  consented  to  the
investigation as part of an ethically approved research project
that  was  performed  in  accordance  with  the  tenets  of  the
Declaration of Helsinki.
Figure  1.  Pedigree  structure  and
haplotype  analysis  of  family  1.  The
diseased  allele  is  indicated  in  black,
while  the  haplotypes  carried  by  the
unaffected parent are indicated red and
yellow.
Figure 2. Fundus signs of affected siblings in family 1. Fundus photographs, autofluorescence, and posterior segment optical coherence
tomography (OCT) images of family 1. A: Individual II:1 (affected sister) had a completely normal left posterior segment examination but
significant retinal pigment epithelium (RPE) layer thickening on the right. B: Individual II:3 (affected brother) had disruption of the inner
segment: outer segment interface. C: Individual II:4 (proband) had exudative vitelliform lesions, demonstrated in the right eye.
Molecular Vision 2011; 17:2272-2282 <http://www.molvis.org/molvis/v17/a247> © 2011 Molecular Vision
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2275RESULTS
The EOG Arden ratios in the normal subjects ranged from
180% to 435% (mean 260%, standard deviation [SD] 50%,
n=30). An abnormal EOG typical for Best disease was defined
as an Arden ratio of <120% [28,29], while 155%–185% was
considered  borderline  or  equivocal,  and  >185%  clearly
normal [30–32]. The upper limits of normal timing (mean±2.5
SD) were 15 min for the dark trough and 12 min for the light
peak.
Proband 1 and family members: A 42-year-old white
female (II:4) with bilateral macular scarring characteristic of
Best  disease  was  reviewed  with  her  three  older  siblings.
Figure 1 shows the pedigree structure. The family was of white
English  ancestry  with  no  history  of  consanguinity.  Both
parents were deceased, and the only available family history
was “poor sight” in the paternal grandmother. Two of the
siblings of II:4 (II:1 and II:3) had clinical findings compatible
with Best disease. Figure 2 shows the fundus signs of the three
affected individuals. The older affected sister, II:1 (Figure 2),
had asymmetric disease, with a normal left fundus appearance
and macular scarring in the right eye. Their affected brother,
II:3 (Figure 2), had bilateral disease, and showed a fundus
appearance  similar  to  that  of  the  proband  (Figure  2).
Autofluorescence  imaging  demonstrated  an  increase  in
lipofuscin accumulation around the macular region with no
scarring in the periphery. Posterior segment OCT imaging
showed  cystoid  macular  lesions,  with  thickening
(hypertrophy and disruption) of the layer between RPE and
the inner segment/ outer segment interface. Their unaffected
sister (II:2) had normal fundus examinations.
Figure 3. Anterior segment optical coherence tomography findings for family 1. A-D: Right eyes of individuals II:1 to II:4 respectively. E-
H: Left eyes of individuals II:1 to II:4 respectively. The unaffected sister (II:2) shown in row 2 had closed angles on anterior segment (AS)-
OCT. Slit openings were observed for individuals II:1 and II:3 on AS-OCT but their angles were closed on gonioscopy. The proband shown
in row 4 had the shallowest anterior chamber depths. H: This shows a thickened cornea from aphakia and corneal decompensation from
previous surgery in the proband.
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2276A summary of the ocular characteristics is shown in Table
2. All four siblings had short axial biometry, but only the
individuals  affected  with  Best  disease  were  found  to  be
hypermetropic. The proband also had evidence of advanced
secondary angle-closure glaucoma (ACG). Pupil-block angle
closure was suspected on anterior segment OCT examination
of the siblings (Figure 3), and was confirmed on dark-room
gonioscopy  where  the  convex  iris  configuration  and
iridotrabecular  contact  in  more  than  180°  of  the  angle
circumference was observed for all four siblings. Both sisters
and the brother of the proband underwent laser iridotomies.
Although the proband (II:4) was the youngest sibling, she had
uncontrolled  ACG,  requiring  multiple  filtration  and  seton
surgery that eventually led to corneal endothelial loss and
significant corneal opacity (OS).
Electrophysiological  testing  showed  normal
electroretinograms. EOGs showed minimal dark trough and
light rise in the proband (II:4) and her affected sister (II:1;
Figure 4). The affected brother (II:3) showed a borderline
EOG light rise of 170% and 160% in the right and left eyes
(Figure 4). His unaffected sister (II:2) had an EOG light rise
Figure  4.  Electrooculography  tracings.  There  is  inter-  and
intrafamilial variability in the electrooculographic (EOG) findings.
Individual  II:2  is  the  only  unaffected  subject,  with  no  clinical
evidence of Best disease, and clearly normal EOG light rises. Both
individuals II:3 and proband 2 demonstrate near-normal EOG light
rises, which is atypical for Best disease.
of 200% bilaterally. Patient II:3 had a slight delay of the light
peak at 14 min, but not the dark trough at 10 min. The other
two affected siblings had normal dark trough and light peak
timings.
Bidirectional Sanger sequencing of BEST1 in the three
affected siblings revealed a base substitution in the coding
region (exon 8), c.914T>C, p.Phe305Ser, but no other variants
(Figure 5). The p.Phe305Ser mutation has previously been
described as segregating in a dominant fashion in another
family with Best disease [1]. The unaffected sibling from this
family was wild type at this allele. The haplotype carrying the
mutation is illustrated in black (Figure 1). The affected brother
(II:3) with a good EOG light rise had the same nondisease
haplotype  (yellow)  as  his  unaffected  sister  (II:2).  Neither
parent  was  available  for  genetic  analysis;  however,  the
markers were informative enough to infer that the affected
brother,  II:3,  had  inherited  a  different  allele  from  the
noncarrier parent (I:2) compared to the other two siblings, II:
1 and II:4 (red). See Figure 1.
Proband 2: An unrelated 53-year-old white female from
the UK presented to the clinic with presumed Best disease
after deterioration of her vision following a viral illness. She
had been diagnosed with macular dystrophy at the age of 40
years. There was a family history of poor sight in her mother
and maternal grandfather, but no clinical details were known.
No  other  family  members  were  available  for  clinical
examination or genetic testing. Her phenotypic characteristics
are  presented  in  Table  2.  Fundus  and  OCT  examinations
showed  significant  accumulation  of  subretinal  fluid  and
central vitelliform lesions (Figure 6). Her refraction and AL
readings fell within the range of all four siblings from family
1, but she had deeper ACDs of 2.83/2.85mm OD/OS, and open
angles on gonioscopy. Her EOG showed a normal dark trough
with a light rise of 170% right eye and 180% left eye (Figure
4).  Dark  trough  and  light  peak  timings  were  normal.
Bidirectional  Sanger  sequencing  of  BEST1  revealed  the
patient to be heterozygous for the same missense variant in
BEST1 as that present in family 1 (c.914T>C, p.Phe305Ser).
DISCUSSION
This report addresses the clinical, electrophysiological, and
genetic findings in two families with dominant Best disease
caused by the same p.Phe305Ser mutation. Very few reports
of BEST1 mutation with normal or equivocal EOGs have
appeared  [12,33–35].  However,  each  of  the  two  families
herein reported contains one individual with an EOG light rise
atypical for the disorder.
Hyperopia of greater than +3.00 diopters is a recognized
a  feature  of  Best  disease  [28].  All  affected  patients  were
hyperopic;  only  the  unaffected  sister  of  proband  1  had  a
normal refraction (Table 2) with a short AL (21.98 mm),
similar to all the affected subjects (range: 20.46–22.60 mm).
Short axial length is a risk factor for developing angle closure,
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2277shared  by  first  degree  relatives  [36].  Although  there  are
relatively few reports of Best disease and ACG [37–39], angle
closure was present in all four siblings of family 1. In other
bestrophinopathies, ACG is relatively common, affecting up
to 50% of cases with ADVIRC [3–7] or ARB [8–10]. Proband
2 did not have angle closure, and this may be explained by her
deeper ACD (Table 2).
Also of note is the completely normal left fundus of
patient II:1. While marked fundus asymmetry can rarely occur
in patients with Best disease [40,41], Testa et al. [35] reported
an Italian family with one of three affected individuals having
a completely normal fundus in one eye. That Italian family
was one of the few reports of a normal EOG in Best disease;
they carried a heterozygous mutation of p.Phe305Leu, the
same amino acid as in this report. A normal fundus appearance
in  both  eyes  of  one  mutation-positive  subject  has  been
described [42] (p.Arg218Cys mutation). The Arden ratio was
175%  in  one  eye,  and  150%  in  the  other.  This  subject’s
affected daughter and grandchildren had findings typical of
Best disease.
An abnormal Arden ratio of <120% is a characteristic
finding in Best disease [28,39], with 155%–185% considered
borderline [30–32]. Both patient II:3 and proband 2 had values
between 160% and 180%, which is atypically high for Best
disease, and which did not occur in other affected family
members who had expectedly severe EOG abnormality. This
inter- and intrafamilial difference in EOG findings suggests
varying  degrees  of  RPE  dysfunction.  A  summary  of  the
clinical  and  electrophysiological  differences  between
disorders caused by BEST1 mutations is shown in Table 3.
Previously described BEST1 mutations associated with
preserved  EOG  include:  p.Phe305Leu  [35],  p.Asp243Val
[12,34],  and  p.Ile295del  [38].  Whole-cell  patch  clamp
analysis in HEK-293 cells by Yu et al. has demonstrated that
the  p.Asp243Val  mutation  causes  approximately  a  90%
reduction  in  chloride-specific  currents  generated  by
bestrophin-1  [43].  The  researchers  also  showed  that  the
p.Ile295del  mutation  completely  abolishes  the  chloride
channel activity of bestrophin-1 [44]. The 305 amino acid
position lies within the C-terminus of BEST1, one of three
mutational hotspots [45]. This is a highly conserved region of
protein sequence close to transmembrane 6, lying on the outer
surface  of  the  protein,  and  may  be  involved  in  charge-
dependent  ligand  binding.  How  the  p.Phe305Ser  and
p.Phe305Leu  mutations  affect  the  in  vitro  activity  of
bestrophin-1  is  yet  to  be  identified  and  warrants  further
investigation.
Currently  unidentified  genetic  mechanisms  such  as  a
single  nucleotide  polymorphism  or  a  small  change  in  the
expression of the wild-type allele in the surrounding sequence
may help to mitigate the EOG light rise. Only one of the three
affected siblings of family 1 demonstrated a near-normal EOG
light rise in the present study. To test the hypothesis that the
nondisease  allele  was  mitigating  the  effect,  microsatellite
markers flanking the BEST1 gene were genotyped. The results
suggested that the nondisease allele from the noncarrier parent
might  determine  the  difference  in  EOG.  This  would  be
consistent  with  reduced  penetrance  of  the  p.Phe305Ser
mutation in abolishing the EOG light rise in some cases.
However, the probability of this occurring by chance alone is
25%.
The role of bestrophin-1 in ocular development, and thus
its role in the development of ACG, has not been elucidated.
Anterior segment changes at the cornea and lens are present
in  ADVIRC,  and  extremes  of  axial  biometry  (range:  16–
25  mm)  can  occur,  depending  on  whether  a  posterior
Figure  5.  Genotype  sequences  for
family 1. The sequence shown on the left
was shared by all three affected siblings,
while  their  unaffected  sister  had  the
wild-type sequence shown on the right.
Figure 6. Fundus signs of proband. Color photographs and posterior segment optical coherence tomography of proband 2. The color
photographs show significant subretinal fluid in both eyes under the central vitelliform lesions, confirmed on optical coherence tomography.
Molecular Vision 2011; 17:2272-2282 <http://www.molvis.org/molvis/v17/a247> © 2011 Molecular Vision
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2279staphyloma is present [5]. Typical fundus signs (Table 3), with
hyperopia and short axial biometry are almost always present
in patients with Best disease [28,37,39] and ARB [8–10]. This
association between BEST1 mutations and ACG is important
for clinicians.
In  conclusion,  this  report  details  unusual  phenotypic
characteristics in two families with Best disease, both carrying
the  same  missense  p.Phe305Ser  mutation.  They  include
mutation-positive patients with a relatively well preserved
EOG light rise; the presence of angle closure in all affected
siblings of family 1; and a completely normal fundus in one
eye  of  one  of  these  affected  patients.  An  effect  of  the
nondisease  allele  is  likely  to  contribute  to  the  reduced
penetrance of the Best disease phenotype, at least for the EOG
light rise. Given the significant risk of ACG, assessment of
angle-closure risk is a necessary consideration in all types of
BEST1 related disease.
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